Dian Diagnostics Group Co.,Ltd.

SZSE:300244 Stock Report

Market Cap: CN¥5.5b

Dian Diagnostics GroupLtd Future Growth

Future criteria checks 3/6

Dian Diagnostics GroupLtd is forecast to grow earnings and revenue by 64.4% and 7.9% per annum respectively. EPS is expected to grow by 64.4% per annum. Return on equity is forecast to be 7.8% in 3 years.

Key information

64.4%

Earnings growth rate

64.4%

EPS growth rate

Healthcare earnings growth21.4%
Revenue growth rate7.9%
Future return on equity7.8%
Analyst coverage

Good

Last updated05 Sep 2024

Recent future growth updates

Dian Diagnostics Group Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Apr 30
Dian Diagnostics Group Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Recent updates

Dian Diagnostics Group Co.,Ltd. (SZSE:300244) Looks Inexpensive But Perhaps Not Attractive Enough

Aug 20
Dian Diagnostics Group Co.,Ltd. (SZSE:300244) Looks Inexpensive But Perhaps Not Attractive Enough

Returns On Capital Signal Tricky Times Ahead For Dian Diagnostics GroupLtd (SZSE:300244)

Jul 12
Returns On Capital Signal Tricky Times Ahead For Dian Diagnostics GroupLtd (SZSE:300244)

Dian Diagnostics GroupLtd (SZSE:300244) Will Pay A Smaller Dividend Than Last Year

Jun 10
Dian Diagnostics GroupLtd (SZSE:300244) Will Pay A Smaller Dividend Than Last Year

Dian Diagnostics GroupLtd (SZSE:300244) Seems To Use Debt Quite Sensibly

May 24
Dian Diagnostics GroupLtd (SZSE:300244) Seems To Use Debt Quite Sensibly

Dian Diagnostics Group Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Apr 30
Dian Diagnostics Group Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Investors Holding Back On Dian Diagnostics Group Co.,Ltd. (SZSE:300244)

Apr 22
Investors Holding Back On Dian Diagnostics Group Co.,Ltd. (SZSE:300244)

Earnings and Revenue Growth Forecasts

SZSE:300244 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202615,5427951,0661,95010
12/31/202514,3396418151,53911
12/31/202413,2244599681,64511
6/30/202412,785-741,0741,615N/A
3/31/202413,1501701,2631,883N/A
12/31/202313,4083071,2201,921N/A
9/30/202314,945-4631,0651,954N/A
6/30/202316,37181,3762,239N/A
3/31/202318,8658411,4442,384N/A
1/1/202320,2821,4346921,639N/A
9/30/202219,3742,358173897N/A
6/30/202218,0452,316-124627N/A
3/31/202214,8631,578102756N/A
1/1/202213,0831,1637281,318N/A
9/30/202112,5151,1361,0501,591N/A
6/30/202111,9671,0291,1151,646N/A
3/31/202111,9851,1359461,456N/A
12/31/202010,6498031,0721,547N/A
9/30/20209,716895407780N/A
6/30/20208,932601221552N/A
3/31/20208,15028199409N/A
12/31/20198,45334772483N/A
9/30/20198,291448164602N/A
6/30/20198,006433-2471N/A
3/31/20197,593398-97423N/A
12/31/20186,967389-83373N/A
9/30/20186,214392-299140N/A
6/30/20185,640373-42731N/A
3/31/20185,169356N/A-49N/A
12/31/20175,004350N/A39N/A
9/30/20174,903325N/A-79N/A
6/30/20174,515308N/A-46N/A
3/31/20174,233279N/A21N/A
12/31/20163,824263N/A132N/A
9/30/20163,147238N/A67N/A
6/30/20162,673221N/A93N/A
3/31/20162,165188N/A84N/A
12/31/20151,858175N/A131N/A
9/30/20151,645161N/A137N/A
6/30/20151,523151N/A160N/A
3/31/20151,411132N/A85N/A
12/31/20141,335125N/A118N/A
9/30/20141,275113N/A123N/A
6/30/20141,178103N/A121N/A
3/31/20141,08290N/A97N/A
12/31/20131,01586N/A75N/A
9/30/201393680N/A65N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300244 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).

Earnings vs Market: 300244 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 300244 is expected to become profitable in the next 3 years.

Revenue vs Market: 300244's revenue (7.9% per year) is forecast to grow slower than the CN market (13.1% per year).

High Growth Revenue: 300244's revenue (7.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300244's Return on Equity is forecast to be low in 3 years time (7.8%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y